Sunday, September 27, 2020
Home Innovation That Matters

Innovation That Matters

Gene Therapy Offers Potentially New Treatment for beta-Thalassemia Patients

Bluebird Bio Inc., a leading gene therapy biotech company based in Cambridge, Massachusetts, announced on February 2 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to one of its investigational drugs, LentiGlobin® BB305 for the treatment of transfusion-dependent patients...

Inside Perspectives: Will Immunotherapy Knock Out Cancer?

The answer is yes, and no. Advances in just the past five years have proven immunotherapy can stimulate the immune system’s natural capabilities to kill cancer cells, and possibly lead to cures for many patients. So yes, it appears immunotherapy is the best weapon yet...

SAGE Therapeutics on Fast Track towards CNS Cures

This month's Innovation that Matters (ITM) features Albert J. Robichaud, Ph.D., chief scientific officer of Cambridge, Mass.-based SAGE Therapeutics, which is developing next-generation medicines for the treatment of rare and life-threatening central nervous system (CNS) disorders.  CNS disorders represent 35 percent of the worldwide...

Gut Instinct: Leveraging the Microbiome and Human Immune System to Dramatically Transform Medicine

By Hui Cai, Vice President of Corporate Alliances and Head of Corporate Communications, WuXi AppTec The drive behind Simba Gill’s success comes from having a deep passion for science, following opportunities regardless of geographical boarders, as well as surrounding himself with talented people. He is also...

Inside Perspectives on Immunotherapy: An Interview with Advaxis CEO Daniel O’Connor

Advaxis Immunotherapies, led by President and CEO Daniel O’Connor, is developing a promising and versatile approach to immuno-oncology with its Listeria monocytogenes (Lm) antigen delivery system. Lm Technology™ shows the immune system how to identify and target tumors, weakens tumor defense mechanisms, and triggers...




Twitter LinkedIn